Does DACOMITINIB Cause Malignant neoplasm progression? 26 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 26 reports of Malignant neoplasm progression have been filed in association with DACOMITINIB (Vizimpro). This represents 3.8% of all adverse event reports for DACOMITINIB.
26
Reports of Malignant neoplasm progression with DACOMITINIB
3.8%
of all DACOMITINIB reports
11
Deaths
6
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DACOMITINIB?
Of the 26 reports, 11 (42.3%) resulted in death, 6 (23.1%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DACOMITINIB. However, 26 reports have been filed with the FAERS database.
What Other Side Effects Does DACOMITINIB Cause?
Death (253)
Diarrhoea (114)
Rash (108)
Neoplasm progression (78)
Paronychia (55)
Blood pressure increased (47)
Off label use (35)
Pruritus (34)
Dyspnoea (30)
Carcinoembryonic antigen increased (28)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DACOMITINIB Alternatives Have Lower Malignant neoplasm progression Risk?
DACOMITINIB vs DACTINOMYCIN
DACOMITINIB vs DALBAVANCIN
DACOMITINIB vs DALFAMPRIDINE
DACOMITINIB vs DALTEPARIN
DACOMITINIB vs DAMOCTOCOG ALFA PEGOL